CLL Society
WHAT’S NEW
Your connection to the most current news, information, and data about Chronic Lymphocytic Leukemia.
We suggest you BOOKMARK this page and visit it often. All content was current as of the date it was published.
In science and in medicine, information is constantly changing. Published content may become out-of-date as new information and data emerge.
Living with CLL
A Patient’s Experience with Pseudo-Richter
When a BTKi is abruptly stopped a surgery, a few patients may have symptoms and pathology that looks like Richter, but is not and responds to restarting the BTKI.
Our CLL Journey
This article is not my CLL journey; this article is our journey. Mine, my wife Michele’s, and my children Jacob (and Sabrina), Rebecca, Emily, and Mathew
CLL Treatment Decision Tool
The goal of the CLL Treatment Decision Tool is to increase your understanding of your chronic lymphocytic leukemia (CLL) and your treatment options.
One Patient’s 10-Year Journey Living With CLL: Hope, Travel, and Community
Judy William’s story is a powerful reminder that a CLL diagnosis doesn’t mean an end to the life you love. It means finding new ways to live it fully.
Dietary and Herbal Supplement Use Among Patients with CLL
Dietary and herbal supplement use is common among patients with CLL with half of patients reporting current or past use.
Dr. Ratner offers his memories through the lens of a physician with CLL who specializes in the care of older adults and as a Support Group facilitator.
WHAT'S NEW IN CLL / SLL
Ask the Expert is now Trusted Care Exchange
You may notice a new name on one of CLL Society’s trusted resources.
Our Ask the Expert program is now called Trusted Care Exchange for CLL / SLL. While the name has changed, the program remains the same helpful resource for patients and care partners looking for trustworthy answers to general questions about CLL or SLL.
Through Trusted Care Exchange, you can submit a question and receive guidance from a vetted advanced practitioner. Questions often relate to symptoms, lab results, medications, side effects, nutrition, and other aspects of living with CLL or SLL.
For those who may benefit from more personalized, in-depth support, CLL Society also offers Expert Access. This program connects patients with a physician for a free second opinion through a HIPAA-compliant video platform when a more detailed review of medical history is needed.
No matter where you are in your journey, we’re here to support you with trusted information, compassionate care, and clinical expertise.
ADVOCACY AND POLICY
CLL Society Supports Clinical Trial Modernization
CLL Society Supports Need for Legally Binding Framework for FDA in Rare Diseases
Designing Part B MFP Effectuation to Preserve Access for Patients with Rare Cancers
CLL Society organized a letter to the CMS arguing the agency use its discretion to implement certain IRA provisions so as to support its patients.
CLL Society Endorses Continued Funding for the NIH
CLL Society Supports Need for Legally Binding Framework for FDA in Rare Diseases
UPCOMING EVENTS
Monday, November 16, 2026, at 9:00 AM PT / 12:00 PM ET
Dr. Daniel Ermann joins us for CLL Society’s Ask Me Anything virtual event. With no prepared presentation, this event is truly dedicated to answering your questions. Dr. Ermann is an Associate Professor specializing in CLL and lymphoma and leads the CLL clinical trials program at Huntsman Cancer Institute, with research focused on targeted therapies, novel treatment combinations, and supportive care. Fellow CLL / SLL patient and advocate Doreen Zetterlund joins us to moderate this event. Doreen is a longtime supporter of the CLL / SLL community and a member of CLL Society’s Patient Advisory Board.
On-Demand Replay
If you missed the recent webinar with Jennifer Woyach, MD and Terry Evans on A Guide to CLL / SLL Treatment Selection and Sequencing, catch the replay, presentation slides, and transcript here! Watch now!
If you missed the recent Q&A-style virtual event “Ask Me Anything” with Dr. Joanna Rhodes and patient advocate Jeff Folloder, you can catch the replay and find the transcript here!
Treatment Updates
Pirtobrutinib plus Venetoclax-Rituximab for Relapsed CLL
Adding pirtobrutinib to venetoclax-rituximab improved progression-free survival in patients with relapsed / refractory CLL.
Updated Results: BTK Degrader Bexobrutideg for Relapsed CLL
BTK degrader bexobrutideg produced high response rates in patients with relapsed CLL who had received a range of different prior therapies.
Pirtobrutinib plus Obinutuzumab for Untreated CLL
In an early analysis, fixed-duration pirtobrutinib plus obinutuzumab shows promise for treating previously untreated CLL.
Equitable Access and Regulatory News
FDA Approves Pirtobrutinib for Some Untreated CLL / SLL
On Oct. 2, 2026, the FDA approved pirtobrutinib as a frontline treatment for CLL / SLL patients who do not have del(17p).
FDA Approves Sonrotoclax for Mantle Cell Lymphoma
On May 13, 2026, the FDA approved sonrotoclax (Beqalzi from BeOne), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL).
FDA Approves Combo of Acalabrutinib and Venetoclax in CLL
The FDA has approved acalabrutinib and venetoclax as the first all oral combination for previously untreated CLL patients based on the AMPLIFY trial data.